Orano Med has opened ATLab Valenciennes in Onnaing, France, giving the company an industrial-scale Pb-212 radiopharmaceutical manufacturing base in Europe as it builds a transatlantic production network around targeted alpha therapy. The more than 3,000-square-meter facility represents an investment of €29 million, approximately $32.6 million at current exchange rates, and is expected to create about 25 direct jobs. Orano Med says the site will initially be capable of producing as many as 10,000 doses annually, with production potential that could eventually increase fivefold at full capacity.
The project was also selected for support under France 2030 following the country's Industrialization and Health Capacities 2030 initiative and received nearly €3.8 million, or about $4.3 million, in public funding. The October 2 inauguration was attended by executives from parent company Orano along with regional officials, partners and other stakeholders. For Orano Med, however, Valenciennes is more than additional manufacturing capacity. It is part of an industrial system being designed around one of Pb-212’s defining characteristics: very little time between production and administration.
Lead-212 has a physical half-life of approximately 10.6 hours, leaving manufacturers with a narrow window in which a radiopharmaceutical can be produced, released, transported and administered before radioactive decay materially reduces the available activity. Orano Med says its Pb-212 therapies must be produced, shipped and administered within approximately 24 hours, making the location of a manufacturing plant part of the product strategy rather than simply a real-estate or operating-cost decision.
ATLab Valenciennes sits about two hours from both Paris-Charles de Gaulle and Brussels-Zaventem airports, and Orano Med estimates that the location can support delivery to hospitals covering nearly 70% of the European population within the required treatment window. That creates a fundamentally different commercial problem from manufacturing a conventional pharmaceutical that can be produced centrally, warehoused and distributed over weeks or months. With Pb-212, usable inventory begins disappearing as soon as it is produced, meaning commercial scale depends not only on how many doses can leave a production line but also on how many can reliably reach treatment centers with sufficient activity remaining.
Orano Med CEO Frederic Desdouits said the facility was designed specifically to provide large-scale production while addressing the logistical constraints created by Pb-212’s half-life. In practice, that means isotope supply, radiolabeling, quality control, pharmaceutical release, transportation and hospital scheduling have to operate as parts of the same production system. The shorter the half-life, the harder it becomes to separate manufacturing strategy from logistics strategy.
Valenciennes sits downstream from another major component of Orano Med’s Pb-212 strategy: control of the precursor material required to generate the isotope. At Bessines-sur-Gartempe in France, the company operates its Maurice Tubiana Laboratory, which produces radium-228 and thorium-228 used upstream in the Pb-212 production chain, while a much larger Advanced Thorium Extraction Facility is under construction to industrialize that process. Orano Med says the ATEF facility will use its proprietary thorium-232 resources and is intended to provide industrial-scale production of thorium-228, the precursor from which Pb-212 is ultimately generated.
The company’s industrial platform is built around a patented chemical separation process that moves through radium-228, thorium-228 and radium-224 before producing Pb-212. Because the process does not depend on a reactor or particle accelerator, Orano Med says it can maintain an integrated isotope-production chain using its own nuclear-material resources rather than relying on an external radionuclide supplier. The ATEF building is expected to be completed in the second half of 2027 and is designed with a modular architecture that could support additional production lines as demand increases.
That buildout received additional financial support in July when the European Investment Bank and Orano signed a €125 million credit line, worth approximately $140.5 million at current exchange rates, to finance Orano Med’s development and industrial infrastructure, including ATEF. The financing reinforces how much of the Pb-212 commercial challenge sits upstream of finished-dose production. Expanding ATLab capacity has limited value without enough precursor material, while abundant precursor supply cannot reach patients without regional pharmaceutical facilities capable of turning it into finished doses quickly enough to overcome radioactive decay.
Orano Med is pursuing the same regional-manufacturing model in North America through ATLab Indianapolis in Brownsburg, Indiana. The roughly 2,800-square-meter facility was inaugurated in 2024 as the first industrial-scale pharmaceutical plant dedicated to Pb-212 targeted alpha therapies and was designed to support large-scale production and distribution across the North American market. Orano Med’s 2026 progress update said both Indianapolis and Valenciennes were moving through commissioning and qualification to support clinical-dose supply in the United States and Europe.
Together, the facilities begin to show what a commercial network for an isotope with a 10.6-hour half-life may have to look like. Instead of relying on one enormous plant serving a global market, the model combines centralized control of longer-lived precursor materials with strategically positioned regional facilities capable of converting those materials into patient-ready radiopharmaceuticals closer to the point of care. The company has already indicated that additional ATLabs could ultimately be needed as it expands geographic coverage and moves more therapies toward commercialization.
That distinction makes annual dose capacity only part of the manufacturing equation. A facility may be capable of producing tens of thousands of doses, but its practical market reach is constrained if those doses cannot move through release, transportation and hospital administration before too much activity has decayed. For Pb-212, manufacturing capacity and distribution radius are therefore closely linked, which makes Orano Med’s claim that Valenciennes can reach hospitals serving nearly 70% of Europe one of the more commercially significant numbers associated with the new plant.
The industrial expansion is arriving as Orano Med’s clinical portfolio broadens. The company says four Pb-212 drug candidates are now in human clinical development through proprietary programs or collaborations with Sanofi, Roche and Molecular Partners, while additional programs remain in preclinical development across multiple cancer types.
Its most advanced program is AlphaMedix, a somatostatin receptor-targeted Pb-212 therapy for neuroendocrine tumors originally developed with RadioMedix and now partnered with Sanofi. Orano Med is also developing Pb-212 approaches across other targeting mechanisms, including MP0712, a DLL3-targeted Radio-DARPin therapy being developed with Molecular Partners for small-cell lung cancer and other neuroendocrine tumors. Molecular Partners and Orano Med announced in July that the first patients had been dosed in the Phase 1/2a study.
The collaboration with Roche explores another approach to matching Pb-212’s short physical half-life with a targeting agent that normally circulates much longer in the body. The partners are developing a pretargeted radioimmunotherapy strategy in which a bispecific antibody is administered first and allowed time to localize to tumor before a separate Pb-212-containing molecule is delivered. Separating those two steps is intended to preserve the biological targeting advantages of an antibody while allowing the short-lived radioactive payload to be administered only after the targeting molecule is already in position.
The breadth of those programs helps explain why Orano Med is building infrastructure before it has a single large commercial Pb-212 product on the market. The company is attempting to establish Pb-212 as a platform capable of supporting different targets, vectors and tumor types, meaning its manufacturing network has to be capable of handling multiple radiopharmaceutical products rather than being constructed around a single asset.
Radiopharmaceutical manufacturing announcements are frequently measured in square footage, production lines and annual dose capacity, and ATLab Valenciennes has substantial numbers across each of those categories. At an initial target of 10,000 doses annually and potential production of as many as 50,000 doses at full capacity, the facility could represent significant European manufacturing capability if Orano Med’s clinical programs continue toward approval and commercialization.
Pb-212, however, exposes the limitations of measuring scale only through nominal production capacity. Its 10.6-hour half-life makes the radius around every manufacturing facility nearly as important as the equipment inside it, while the need for a reliable stream of thorium-228 precursor makes upstream isotope control equally important. Orano Med is therefore building two interconnected systems: a precursor network intended to secure and scale the nuclear material required for Pb-212 production, and a regional pharmaceutical network designed to convert that material into patient doses close enough to hospitals for those doses to remain clinically useful.
Valenciennes, Indianapolis, the Maurice Tubiana Laboratory and the ATEF facility each solve a different part of that industrial problem. As targeted alpha therapy moves toward larger trials and potential commercial launches, having an effective radiopharmaceutical and access to an alpha-emitting isotope will not be enough if the manufacturing system cannot repeatedly deliver the required activity to the right hospital at the right time.
The significance of ATLab Valenciennes is therefore larger than the opening of another radiopharmaceutical plant. It shows the physical infrastructure beginning to form around a Pb-212 commercial model in which isotope production, regional manufacturing and logistics cannot easily be separated from one another. For very short-lived radiopharmaceuticals, the supply chain is increasingly becoming part of how the therapy itself has to be designed and commercialized.
